CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$18.25M, compared with $23.53M a year earlier. Trailing-twelve-month net income was -$59.14M. Over 3 fiscal years it compounded at -44.1% a year.
Context
- Net income amounted to 22.8% of revenue in FY2025, down 0.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$53.82M (+209.9%) for the fiscal year ending Dec 2026, a step up from the -154.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.25M-31.2% QoQ
- Last fiscal yearDec 2025
- -$17.37M-154.5% YoY
- LTMMar 2026
- -$59.14M-242.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (17.37M) USD
- Year-over-year change
- -154.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.37M) | -154.5% |
| FY2024 | 2024-12-31 | 31.87M | +5700.9% |
| FY2023 | 2023-12-31 | (569K) | +99.4% |
| FY2022 | 2022-12-31 | (99.32M) | -18.8% |
| FY2021 | 2021-12-31 | (83.61M) | — |
Net Income vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 net income of $59.14M is the 8th largest of the 10 companies compared; the peer median is $71.19M.
- Its year-over-year change of -242.2% is the lowest of 9, against a peer median of +8.7%.
- Net income amounts to 166.4% of revenue for CTMX, versus a peer median of 154.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $309.06M | +37.6% | +32.1% | 275948.2% | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $153.6M | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
| LTM Jun 2026 | $71.19M | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $59.14M | -242.2% | -44.1% | 166.4% | |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $71.19M | +8.7% | +5.2% | 154.2% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.61M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Depreciation & Amortization | 2.71M | 5.86M | 2.18M | 1.77M | 1.38M |
| Deferred Income Tax | 272K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.17M | 13.13M | 8.56M | 7.67M | 6.3M |
| Change in Working Capital | (54.7M) | (30.65M) | (62.51M) | (126.42M) | (68.58M) |
| Accounts Receivables | 8K | (35.2M) | 32.55M | 329K | 1.09M |
| Inventory | 11.64M | 0 | 0 | 0 | 0 |
| Accounts Payables | (139K) | 68K | (1.43M) | (297K) | 221K |
| Other Working Capital | (66.21M) | 4.47M | (93.64M) | (126.45M) | (69.89M) |
| Other Non-Cash Items | 3.13M | 13.33M | (3.69M) | (1.12M) | 2.68M |
| Operating Cash Flow | (119.03M) | (110.79M) | (56.04M) | (86.23M) | (75.59M) |
| Capital Expenditures | (1.61M) | (1.74M) | (840K) | (310K) | (220K) |
| Acquisitions (Net) | (24.1M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.9M) | 0 | (424.83M) | (155.49M) | (192.52M) |
| Sales of Investments | 124M | 100M | 275M | 255.5M | 133M |
| Other Investing Activities | 24.1M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 22.49M | 98.26M | (150.67M) | 99.7M | (59.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 107.71M | 648K | 30.23M | 6.91M | 110.45M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.5M | 0 | 0 | 613K | 0 |
| Financing Cash Flow | 110.21M | 648K | 30.23M | 7.52M | 110.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 13.67M | (11.88M) | (176.48M) | 20.99M | (24.89M) |
| Free Cash Flow | (120.64M) | (112.53M) | (56.88M) | (86.54M) | (75.81M) |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.